Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial (Q38440924)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial |
scientific article |
Statements
1 reference
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial (English)
1 reference
Michael J Koren
David Sullivan
Michael Bolognese
Gisle Langslet
Fernando Civeira
Ransi Somaratne
Patric Nelson
Thomas Liu
Scott M Wasserman
Marc S Sabatine
OSLER Investigators
19 November 2013
1 reference